Video

Dr. Singal Discusses Recent Clinical Trials in HCC

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses recent clinical trials in hepatocellular carcinoma.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses recent clinical trials in hepatocellular carcinoma (HCC).

The phase III CELESTIAL trial tested cabozantinib (Cabometyx) versus placebo in the second-line setting for patients with advanced HCC. Interestingly, Singal says, about 25% of the patient cohort had received 2 prior lines of systemic therapy, suggesting that cabozantinib may even be a third-line agent. Data showed that cabozantinib improved survival in the second line compared with placebo.

The REACH-2 trial was informed by a negative phase III study, Singal says. Initially, ramucirumab (Cyramza) was tested versus placebo in the second line for all-comers. In a post-hoc analysis, researchers found there was a potential benefit in patients with a high alpha-fetoprotein (AFP) level. This led to the second trial of ramucirumab versus placebo in patients with high AFP. There was a survival benefit in those patients. This could suggest that AFP is a potential biomarker for the treatment of patients with advanced HCC, Singal says.

Related Videos
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Alicia Morgans, MD, MPH, genitourinary medical oncologist, medical director, Survivorship Program, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD